Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Breast Neoplasms 4Sarcoma 2Triple Negative Breast Neoplasms 1Sarcoma, Synovial 1Pheochromocytoma 1Neurofibrosarcoma 1Neuroblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Liposarcoma 1Leiomyosarcoma 1Inflammatory Breast Neoplasms 1Histiocytoma, Malignant Fibrous 1Hematologic Neoplasms 1Fibrosarcoma 1Breast Neoplasms, Male 1

Interventions

Cyclophosphamide 5Melphalan 4Isotretinoin 4Etoposide 4Carboplatin 4Vincristine 3Therapeutics 3Radiotherapy 3Cisplatin 3Topotecan 2Stem Cell Transplantation 2Radiotherapy, Image-Guided 2Psychiatric Rehabilitation 2Granulocyte-Macrophage Colony-Stimulating Factor 2Granulocyte Colony-Stimulating Factor 2Doxorubicin 2Dexamethasone 2Calcium Dobesilate 2Busulfan 2Blood Specimen Collection 2Aprepitant 23-Iodobenzylguanidine 2sargramostim 1pegfilgrastim 1humanized 3F8 anti-GD2 monoclonal antibody 1hetrombopag 1etoposide phosphate 1dexamethasone acetate 1dexamethasone 21-phosphate 1Whole-Body Irradiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Neuroblastoma × pegfilgrastim × Clear all
NCT01850888 2025-12-18

MIBG for Refractory Neuroblastoma and Pheochromocytoma

Masonic Cancer Center, University of Minnesota

Phase NA Completed
15 enrolled
CNSEndocrine

Neuroblastoma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡